Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
Public ClinicalTrials.gov record NCT00322218. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III,Open-label,Prospective,Two-armed,Multicenter Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study treats patients with diffuse large B-cell lymphoma whose disease is in complete remission due to previous treatment with Cyclophosphamide Doxorubicin hydrochloride Vincristine Prednisolone- Rituximab (CHOP-R). Half of the patients received Zevalin and the other half receive no further anti-cancer treatment. The two patient groups compared to determine if Zevalin given after CHOP-R therapy provides greater benefits than receiving no additional anti-cancer therapy after CHOP-R.
Study identification
- NCT ID
- NCT00322218
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 68 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2006 (Type not available)
- Primary completion
- Dec 2008 (Actual)
- Completion
- Dec 2008 (Actual)
- Last update posted
- Jan 19, 2022
2006 – 2008
United States locations
- U.S. sites
- 34
- U.S. states
- 19
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Mesa | Arizona | — | — |
| Research Site | Phoenix | Arizona | — | — |
| Research Site | Scottsdale | Arizona | — | — |
| Research site | Bakersfield | California | — | — |
| Research Site | Berkeley | California | — | — |
| Research Site | Beverly Hills | California | — | — |
| Research Site | Burbank | California | — | — |
| Research Site | Duarte | California | — | — |
| Research site | Los Angeles | California | — | — |
| Research site | Newport Beach | California | — | — |
| Research Site | San Diego | California | — | — |
| Research site | Vallejo | California | — | — |
| Research site | Aurora | Colorado | — | — |
| Research site | Newark | Delaware | — | — |
| Research site | St. Petersburg | Florida | — | — |
| Research Site | Coeur d'Alene | Idaho | — | — |
| Research site | Chicago | Illinois | — | — |
| Research site | Joliet | Illinois | — | — |
| Research Site | Morris | Illinois | — | — |
| Research site | Overland Park | Kansas | — | — |
| Research Site | Shreveport | Louisiana | — | — |
| Research site | Baltimore | Maryland | — | — |
| Research site | Boston | Massachusetts | — | — |
| Research site | Detroit | Michigan | — | — |
| Research Site | Rochester | Minnesota | — | — |
| Research Site | Saint Louis Park | Minnesota | — | — |
| Research Site | Commack | New York | — | — |
| Research Site | East Setauket | New York | — | — |
| Research Site | Durham | North Carolina | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Aberdeen | South Dakota | — | — |
| Research Site | Dallas | Texas | — | — |
| Research Site | Houston | Texas | — | — |
| Research Site | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00322218, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2022 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00322218 live on ClinicalTrials.gov.